SMT201600088B - Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi - Google Patents
Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidiInfo
- Publication number
- SMT201600088B SMT201600088B SM201600088T SM201600088T SMT201600088B SM T201600088 B SMT201600088 B SM T201600088B SM 201600088 T SM201600088 T SM 201600088T SM 201600088 T SM201600088 T SM 201600088T SM T201600088 B SMT201600088 B SM T201600088B
- Authority
- SM
- San Marino
- Prior art keywords
- opiousid
- buprenorphine
- agonists
- analogues
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38491210P | 2010-09-21 | 2010-09-21 | |
| US201161503674P | 2011-07-01 | 2011-07-01 | |
| PCT/IB2011/002208 WO2012038813A1 (en) | 2010-09-21 | 2011-09-20 | Buprenorphine analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600088B true SMT201600088B (it) | 2016-04-29 |
Family
ID=44903285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600088T SMT201600088B (it) | 2010-09-21 | 2016-03-24 | Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9221831B2 (xx) |
| EP (1) | EP2619212B1 (xx) |
| JP (2) | JP5977240B2 (xx) |
| KR (2) | KR20150027315A (xx) |
| CN (2) | CN105399751A (xx) |
| AR (1) | AR083062A1 (xx) |
| AU (1) | AU2011306644B2 (xx) |
| CA (1) | CA2810356C (xx) |
| CL (1) | CL2013000732A1 (xx) |
| CO (1) | CO6690803A2 (xx) |
| CR (1) | CR20130129A (xx) |
| CY (1) | CY1117227T1 (xx) |
| DK (1) | DK2619212T3 (xx) |
| DO (1) | DOP2013000060A (xx) |
| EA (1) | EA201390422A1 (xx) |
| EC (1) | ECSP13012543A (xx) |
| ES (1) | ES2566828T3 (xx) |
| HK (1) | HK1187045A1 (xx) |
| HR (1) | HRP20160281T1 (xx) |
| HU (1) | HUE027195T2 (xx) |
| ME (1) | ME02367B (xx) |
| MX (1) | MX2013003354A (xx) |
| NI (1) | NI201300032A (xx) |
| NZ (1) | NZ609200A (xx) |
| PE (1) | PE20140020A1 (xx) |
| PL (1) | PL2619212T3 (xx) |
| RS (1) | RS54579B1 (xx) |
| SG (1) | SG188300A1 (xx) |
| SI (1) | SI2619212T1 (xx) |
| SM (1) | SMT201600088B (xx) |
| TW (2) | TW201422621A (xx) |
| UY (1) | UY33618A (xx) |
| WO (1) | WO2012038813A1 (xx) |
| ZA (1) | ZA201301217B (xx) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US8846765B2 (en) | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| PT2707361T (pt) | 2011-05-10 | 2017-11-28 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de sódio |
| NO3175985T3 (xx) | 2011-07-01 | 2018-04-28 | ||
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| US9096606B2 (en) | 2011-12-08 | 2015-08-04 | Purdue Pharma, L.P. | Quarternized buprenorphine analogs |
| US9315514B2 (en) * | 2012-08-27 | 2016-04-19 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
| US10138207B2 (en) | 2012-11-09 | 2018-11-27 | Purdue Pharma, L.P. | Benzomorphan analogs and the use thereof |
| JP6317755B2 (ja) * | 2012-12-07 | 2018-04-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド受容体モジュレーターとしてのブプレノルフィン類似体 |
| US9056836B2 (en) | 2013-01-31 | 2015-06-16 | Purdue Pharma L.P. | Benzomorphan analogs and the use thereof |
| US8969358B2 (en) * | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
| CA2934913A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Ring-contracted morphinans and the use thereof |
| EP3089982A4 (en) * | 2013-12-26 | 2017-09-27 | Purdue Pharma L.P. | 7-beta analogs of orvinols |
| EP3087073B1 (en) | 2013-12-26 | 2018-07-04 | Purdue Pharma LP | 10-substituted morphinan hydantoins |
| US9988392B2 (en) | 2013-12-26 | 2018-06-05 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
| WO2015097545A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
| EP3086790A4 (en) | 2013-12-27 | 2017-07-19 | Purdue Pharma LP | 6-substituted and 7-substituted morphinan analogs and the use thereof |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| JP2017521373A (ja) | 2014-05-27 | 2017-08-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | スピロ環モルフィナン及びその使用 |
| MA40171A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés d'azamophinan et leur utilisation |
| MA41125A (fr) | 2014-12-05 | 2017-10-10 | Purdue Pharma Lp | Dérivés de 6.7-cyclomorphinane et leur utilisation |
| SG11201803268TA (en) * | 2015-10-26 | 2018-05-30 | Orphomed Inc | Ethylene glycol ether of buprenorphine |
| FI3390355T3 (fi) * | 2016-03-22 | 2023-04-04 | Helsinn Healthcare Sa | Asymmetrisiä bentseenisulfonyyliureoita ja niiden lääketieteellisiä käyttöjä |
| WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
| CA3063975A1 (en) * | 2017-05-19 | 2018-11-22 | River Stone Biotech Aps | Preparation of buprenorphine |
| JP2021104932A (ja) * | 2018-03-30 | 2021-07-26 | 日本ケミファ株式会社 | モルヒナン誘導体の製造方法 |
| WO2024044179A1 (en) * | 2022-08-23 | 2024-02-29 | Virginia Commonwealth University | Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1136764A (en) * | 1965-08-13 | 1968-12-18 | Reckitt & Sons Ltd | Derivatives of thebaine and oripavine |
| ATE276242T1 (de) | 1997-05-30 | 2004-10-15 | Banyu Pharma Co Ltd | 2-oxoimidazol-derivate |
| WO1999048492A1 (fr) | 1998-03-26 | 1999-09-30 | Japan Tobacco Inc. | Derives d'amide et antagonistes de nociceptine |
| JP2004538256A (ja) | 2001-03-02 | 2004-12-24 | ユーロ−セルティーク，エス．エイ． | Ｎ−ブト−３−エチル＝ノルブプレノルフィン及び使用方法 |
| US6740641B2 (en) | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
| MXPA05003104A (es) | 2002-09-25 | 2005-05-27 | Euro Celtique Sa | Hidromorfonas n-sustituidas y uso de las mismas. |
| ATE444296T1 (de) | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
| US7202259B2 (en) | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US6958398B1 (en) | 2002-12-30 | 2005-10-25 | Euro-Celtique S.A. | Methods for making thebaine or its acid salts |
| WO2008053352A2 (en) | 2006-11-01 | 2008-05-08 | Purdue Pharma L.P. | Phenylpropionamide compounds and the use thereof |
| GB2447014A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| EP2620437A1 (en) | 2007-11-30 | 2013-07-31 | Purdue Pharma LP | Benzomorphan compounds |
| DK2326651T3 (da) * | 2008-07-30 | 2014-01-20 | Purdue Pharma Lp | Buprenorphinanaloger |
| US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| US9096606B2 (en) | 2011-12-08 | 2015-08-04 | Purdue Pharma, L.P. | Quarternized buprenorphine analogs |
| EP2858976B1 (en) | 2012-05-11 | 2018-03-14 | Purdue Pharma LP | Benzomorphan compounds as opioid receptors modulators |
| US9315514B2 (en) | 2012-08-27 | 2016-04-19 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
| US10138207B2 (en) | 2012-11-09 | 2018-11-27 | Purdue Pharma, L.P. | Benzomorphan analogs and the use thereof |
| JP6317755B2 (ja) | 2012-12-07 | 2018-04-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド受容体モジュレーターとしてのブプレノルフィン類似体 |
| ES2631197T3 (es) | 2012-12-14 | 2017-08-29 | Purdue Pharma Lp | Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes |
| EP2931725B1 (en) | 2012-12-14 | 2017-02-15 | Purdue Pharma LP | Nitrogen containing morphinan derivatives and the use thereof |
| US8987287B2 (en) | 2012-12-14 | 2015-03-24 | Purdue Pharma L.P. | Spirocyclic morphinans and their use |
| CA2896202A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
| TW201441198A (zh) | 2012-12-28 | 2014-11-01 | Purdue Pharma Lp | ７，８－環嗎啡喃類似物 |
| US9056836B2 (en) | 2013-01-31 | 2015-06-16 | Purdue Pharma L.P. | Benzomorphan analogs and the use thereof |
| US8969358B2 (en) | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
| EP3087073B1 (en) | 2013-12-26 | 2018-07-04 | Purdue Pharma LP | 10-substituted morphinan hydantoins |
| WO2015097546A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Propellane-based compounds and their use as opioid receptor modulators |
| US9988392B2 (en) | 2013-12-26 | 2018-06-05 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
| EP3089982A4 (en) | 2013-12-26 | 2017-09-27 | Purdue Pharma L.P. | 7-beta analogs of orvinols |
| EP3086790A4 (en) | 2013-12-27 | 2017-07-19 | Purdue Pharma LP | 6-substituted and 7-substituted morphinan analogs and the use thereof |
| WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
-
2011
- 2011-09-20 WO PCT/IB2011/002208 patent/WO2012038813A1/en active Application Filing
- 2011-09-20 ME MEP-2016-38A patent/ME02367B/me unknown
- 2011-09-20 KR KR20157004529A patent/KR20150027315A/ko not_active Application Discontinuation
- 2011-09-20 CA CA2810356A patent/CA2810356C/en not_active Expired - Fee Related
- 2011-09-20 MX MX2013003354A patent/MX2013003354A/es not_active Application Discontinuation
- 2011-09-20 RS RS20160119A patent/RS54579B1/en unknown
- 2011-09-20 US US13/825,241 patent/US9221831B2/en active Active
- 2011-09-20 HU HUE11776855A patent/HUE027195T2/en unknown
- 2011-09-20 CN CN201510733006.4A patent/CN105399751A/zh active Pending
- 2011-09-20 AU AU2011306644A patent/AU2011306644B2/en not_active Ceased
- 2011-09-20 SG SG2013014113A patent/SG188300A1/en unknown
- 2011-09-20 KR KR1020137009943A patent/KR101630912B1/ko active IP Right Grant
- 2011-09-20 PE PE2013000548A patent/PE20140020A1/es not_active Application Discontinuation
- 2011-09-20 AR ARP110103431A patent/AR083062A1/es unknown
- 2011-09-20 SI SI201130750T patent/SI2619212T1/sl unknown
- 2011-09-20 PL PL11776855.6T patent/PL2619212T3/pl unknown
- 2011-09-20 CN CN2011800450775A patent/CN103154000A/zh active Pending
- 2011-09-20 DK DK11776855.6T patent/DK2619212T3/en active
- 2011-09-20 UY UY0001033618A patent/UY33618A/es unknown
- 2011-09-20 ES ES11776855.6T patent/ES2566828T3/es active Active
- 2011-09-20 EP EP11776855.6A patent/EP2619212B1/en active Active
- 2011-09-20 EA EA201390422A patent/EA201390422A1/ru unknown
- 2011-09-20 NZ NZ609200A patent/NZ609200A/en not_active IP Right Cessation
- 2011-09-20 JP JP2013529723A patent/JP5977240B2/ja not_active Expired - Fee Related
- 2011-09-21 TW TW102147960A patent/TW201422621A/zh unknown
- 2011-09-21 TW TW100133950A patent/TW201242968A/zh unknown
-
2013
- 2013-02-18 ZA ZA2013/01217A patent/ZA201301217B/en unknown
- 2013-03-18 CL CL2013000732A patent/CL2013000732A1/es unknown
- 2013-03-20 DO DO2013000060A patent/DOP2013000060A/es unknown
- 2013-03-20 NI NI201300032A patent/NI201300032A/es unknown
- 2013-03-21 CR CR20130129A patent/CR20130129A/es not_active Application Discontinuation
- 2013-04-05 EC ECSP13012543 patent/ECSP13012543A/es unknown
- 2013-04-18 CO CO13100225A patent/CO6690803A2/es unknown
- 2013-12-30 HK HK13114384.0A patent/HK1187045A1/xx not_active IP Right Cessation
-
2015
- 2015-11-19 JP JP2015226945A patent/JP2016102115A/ja not_active Withdrawn
-
2016
- 2016-03-04 CY CY20161100187T patent/CY1117227T1/el unknown
- 2016-03-18 HR HRP20160281TT patent/HRP20160281T1/hr unknown
- 2016-03-24 SM SM201600088T patent/SMT201600088B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600088B (it) | Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi | |
| CY2023022I1 (el) | Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης | |
| CY2020018I1 (el) | Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων | |
| IL245471B (en) | Fluorinated compounds as alpha v integrin receptor antagonists | |
| ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
| EP2655409A4 (en) | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 | |
| BR112014014547A2 (pt) | compostos antagonistas de e-selectina, composições e métodos de uso | |
| ES2969067T3 (es) | Formulaciones de agonistas de guanilato ciclasa C y métodos de utilización | |
| ZA201307115B (en) | Androgen receptor antagonists and uses thereof | |
| RS57232B1 (sr) | Jedinjenja koja imaju muskarinske receptore aktivnosti antagonista i beta2 adrenergik receptore aktivnosti agonista | |
| SMT201600150B (it) | Antagonisti di trpv4 | |
| SMT201700064B (it) | Antagonisti di d2, metodi di sintesi e metodi di uso | |
| BR112013029482A2 (pt) | utilização de antagonistas cxr4 | |
| BR112013022552A2 (pt) | compostos de quinazolina substituídos com alcino e métodos de uso | |
| DK3312169T3 (da) | 5-ht3 receptorantagonister | |
| BR112014012409A2 (pt) | composições de buprenorfina e antagonistas do receptor mu-opiódie | |
| ZA201306744B (en) | Antagonists of the interleukin-1 receptor | |
| SMT201500296B (it) | Antagonisti del recettore trpm8 | |
| ZA201307986B (en) | Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists | |
| DK2861209T3 (da) | Somatostatinreceptoragonistformuleringer | |
| DK2877173T3 (da) | Antagonister / inverse agonister til cannabinoidreceptorer | |
| HK1211588A1 (en) | Antagonists of chemokine receptors | |
| FR2957050B1 (fr) | Plancher d'aeronef | |
| IL237150B (en) | Preparations containing combinations of receptor antagonists and agonists | |
| EP2999967A4 (en) | Use of tenascin-c as an extracellular marker of tumor-derived microparticles |